To include your compound in the COVID-19 Resource Center, submit it here.

Opdivo nivolumab: Additional Phase II data

Additional data from the U.S. and French Phase II CheckMate -069 trial in 142 patients with previously untreated unresectable stage 3/4 melanoma showed that Opdivo plus Yervoy ipilimumab followed by Opdivo alone led

Read the full 336 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers